Literature DB >> 8113593

Serum arginase level in patients with gastric cancer.

C W Wu1, C W Chi, E C Lin, W Y Lui, F K P'eng, S R Wang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8113593     DOI： 10.1097/00004836-199401000-00019

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN： 0192-0790            Impact factor:   3.062


× No keyword cloud information.
  8 in total

Review 1.  Metabolic mechanisms of tumor resistance to T cell effector function.

Authors:  Candace M Cham; Thomas F Gajewski
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Effect of arginase on splenic killer cell activity in patients with gastric cancer.

Authors:  C W Wu; C W Chi; C K Ho; S L Chien; W Y Liu; F K P'eng; S R Wang
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

3.  Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy.

Authors:  Matthew J Mitcheltree; Derun Li; Abdelghani Achab; Adam Beard; Kalyan Chakravarthy; Mangeng Cheng; Hyelim Cho; Padmanabhan Eangoor; Peter Fan; Symon Gathiaka; Hai-Young Kim; Charles A Lesburg; Thomas W Lyons; Theodore A Martinot; J Richard Miller; Spencer McMinn; Jennifer O'Neil; Anandan Palani; Rachel L Palte; Josep Saurí; David L Sloman; Hongjun Zhang; Jared N Cumming; Christian Fischer
Journal:  ACS Med Chem Lett       Date:  2020-03-23       Impact factor: 4.345

4.  Immunohistochemical study of arginase in cancer of the stomach.

Authors:  C W Wu; W W Chung; C W Chi; H L Kao; W Y Lui; F K P'eng; S R Wang
Journal:  Virchows Arch       Date:  1996-08       Impact factor: 4.064

5.  Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma.

Authors:  Amit Mittal; Mike Wang; Aurobind Vidyarthi; Diana Yanez; Gabriela Pizzurro; Durga Thakral; Erin Tracy; Oscar R Colegio
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.996

6.  Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.

Authors:  Juan J Miret; Paul Kirschmeier; Shohei Koyama; Mingrui Zhu; Yvonne Y Li; Yujiro Naito; Min Wu; Venkat S Malladi; Wei Huang; William Walker; Sangeetha Palakurthi; Glenn Dranoff; Peter S Hammerman; Chad V Pecot; Kwok-Kin Wong; Esra A Akbay
Journal:  J Immunother Cancer       Date:  2019-02-06       Impact factor: 13.751

7.  Altered molecular pathways and prognostic markers in active systemic juvenile idiopathic arthritis: integrated bioinformatic analysis.

Authors:  Yi Ren; Hannah Labinsky; Andriko Palmowski; Henrik Bäcker; Michael Müller; Arne Kienzle
Journal:  Bosn J Basic Med Sci       Date:  2022-04-01       Impact factor: 3.363

8.  OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer.

Authors:  Marcin Mikołaj Grzybowski; Paulina Seweryna Stańczak; Paulina Pomper; Roman Błaszczyk; Bartłomiej Borek; Anna Gzik; Julita Nowicka; Karol Jędrzejczak; Joanna Brzezińska; Tomasz Rejczak; Nazan Cemre Güner-Chalimoniuk; Agnieszka Kikulska; Michał Mlącki; Jolanta Pęczkowicz-Szyszka; Jacek Olczak; Adam Gołębiowski; Karolina Dzwonek; Paweł Dobrzański; Zbigniew Zasłona
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.